AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Summary

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Refractory Rheumatoid Arthritis (RA)
• Idiopathic Inflammatory Myopathies (IIMs)
• Systemic Sclerosis (SSc)
• Rheumatoid Arthritis (RA
• IIM
• Myositis
• Scleroderma
• Sjogren Syndrome
• Sjogrens Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Artiva Biotherapeutics, Inc.

Last updated on ClinicalTrials.gov

July 31, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites